References
- EsteyEDöhnerHAcute myeloid leukemiaLancet200636895501894190717126723
- DavilaJSlotkinERenaudTRelapsed and refractory pediatric acute myeloid leukemia: current and emerging treatmentsPaediatr Drugs201416215116824158739
- EsteyEHTreatment of acute myeloid leukemiaHaematologica2009941101619118375
- PlataniasLCMap kinase signaling pathways and hematologic malignanciesBlood2003101124667467912623839
- MartelliAMEvangelistiCChiariniFGrimaldiCManzoliLMcCubreyJATargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemiaExpert Opin Investig Drugs200918913331349
- NishiokaCIkezoeTYangJYokoyamaAInhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cellsApoptosis20091491108112019548087
- KhokharNZAltmanJKPlataniasLCEmerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignanciesCurr Opin Oncol201123657858621892085
- WangXYuePChanCBInhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylationMol Cell Biol200727217405741317724079
- HouJLamFProudCWangSTargeting Mnks for cancer therapyOncotarget20123211813122392765
- DiabSKumarasiriMYuMMAP kinase-interacting kinases–emerging targets against cancerChem Biol201421444145224613018
- SonenbergNGingrasACThe mRNA 5′cap-binding protein eIF4E and control of cell growthCurr Opin Cell Biol19981022682759561852
- TopisirovicIGuzmanMLMcConnellMJAberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesisMol Cell Biol200323248992900214645512
- AltmanJKSzilardAKonicekBWInhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursorsBlood2013121183675368123509154
- BartelDPMicroRNAs: genomics, biogenesis, mechanism, and functionCell2004116228129714744438
- SunCCLiSJLiDJHsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1Oncotarget2016724359603597827166267
- LiuYZhangMQianJmiR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal transition by targeting KRAS in renal cell carcinoma cellsDNA Cell Biol201534642943625811077
- MooreASKearnsPRKnapperSPearsonADZwaanCMNovel therapies for children with acute myeloid leukemiaLeukemia20132771451146023563239
- GalmariniCMThomasXCalvoFIn vivo mechanisms of resistance to cytarabine in acute myeloid leukemiaBr J Haematol2002117486086812060121
- KannoSHiuraTOhtakeTCharacterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cellsClin Chim Acta20073771–214414917097625
- SarkarMHanTDamarajuVCarpenterPCassCEAgarwalRPCytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cellsBiochem Pharmacol200570342643215950950
- KitamuraKSeikeMOkanoTMiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cellsMol Cancer Ther201413244445324258346
- ShuangTWangMShiCZhouYWangDDown-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cellsFEBS Lett201558920 Pt B3154316426363097
- O’BrienKLowryMCCorcoranCmiR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivityOncotarget2015632327743278926416415
- MartelliAMEvangelistiCChiariniFMcCubreyJAThe phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patientsOncotarget2010128910320671809
- MartelliAMTazzariPLEvangelistiCTargeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedsideCurr Med Chem200714192009202317691943
- LiPDiabSYuMInhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cellsOncotarget2016735568115682527462781